Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF Duration and Growth Factor for GVHD Prophylaxis in Hematological Malignancies
NCT02593123Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Nov 2015
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mycophenolate mofetil, sargramostim in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), sponsored by Virginia Commonwealth University. Started Nov 2015; status: completed.
02
Drugs
mycophenolate mofetilsargramostim
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02593123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593123.